Cellectis S.A. (NASDAQ:CLLS) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. trimmed its position in Cellectis S.A. (NASDAQ:CLLS) by 1.9% in the third quarter, HoldingsChannel.com reports. The firm owned 693,939 shares of the biotechnology company’s stock after selling 13,691 shares during the quarter. Baillie Gifford & Co.’s holdings in Cellectis were worth $1,485,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. First Affirmative Financial Network bought a new stake in Cellectis in the third quarter worth about $45,000. XTX Topco Ltd acquired a new stake in Cellectis in the 2nd quarter valued at about $29,000. Finally, Principal Financial Group Inc. boosted its position in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares in the last quarter. 63.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on CLLS. StockNews.com assumed coverage on shares of Cellectis in a research note on Wednesday. They set a “sell” rating for the company. Barclays reduced their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Price Performance

CLLS stock opened at $1.98 on Thursday. Cellectis S.A. has a one year low of $1.70 and a one year high of $3.77. The firm has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.25. The firm has a market capitalization of $110.06 million, a PE ratio of -1.52 and a beta of 3.10. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. During the same period in the prior year, the business posted ($0.31) EPS. On average, analysts forecast that Cellectis S.A. will post -0.46 earnings per share for the current year.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.